NetScientific Shares Rise After FDA Meeting on HPV Carcinoma Therapy
October 03 2022 - 10:10AM
Dow Jones News
By Michael Susin
NetScientific PLC shares rose on Monday after the company said
that its portfolio company PDS Biotechnology Corp. has successfully
completed an end-of-Phase-2 meeting with the U.S. Food and Drug
Administration regarding the combination of its treatment with
Merck & Co.'s therapy for papillomavirus carcinoma.
Shares at 1307 GMT were up 0.05 pence, or 13%, at 0.5 pence.
The life-sciences and technology investment company said that
PDS has received guidance from FDA on key elements to submit a
biologics license application for its PDS0101 asset treatment.
The end-of-Phase-2 meeting was to determine the safety of
proceeding to the last phase of the study and identify any
additional information necessary to support a marketing application
for the uses under investigation.
The combined therapies are targeting the treatment of
unresectable, recurrent and metastatic
human-papillomavirus-16-positive head-and-neck squamous-cell
carcinoma, the company added.
"We are pleased with PDS's continued and systematic progress on
its business objectives, despite unfavorable capital markets
conditions. Building on momentum from the FDA Fast Track
designation in June 2022, and the subsequent $35 million venture
debt facility in August 2022, PDS is now well positioned for
further progress in its PDS0101 clinical program." Chief Executive
Officer Dr. Ilian Iliev said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
October 03, 2022 09:55 ET (13:55 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Netscientific (LSE:NSCI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From Mar 2023 to Mar 2024